Detailed Narrative
Strong Commercial Execution Drives Record Q1 Revenues
Jazz Pharmaceuticals reported an exceptionally strong first quarter, achieving its highest ever first quarter total revenues of $1.1 billion, representing over 19% year-over-year growth. This performance was driven by robust commercial execution across its highly differentiated product portfolio, including Xywav, Epidiolex, Modeyso, and Zepzelca, all of which demonstrated double-digit growth. The company highlighted disciplined efforts by its commercial teams in supporting physicians and patients.
Zanidatamab Progress in HER2-positive GEA
The company is urgently advancing zanidatamab for patients with HER2-positive first-line locally advanced or metastatic GEA, an area of significant unmet medical need. The FDA recently accepted the sBLA for Ziihera under real-time oncology review, granting Priority Review with a PDUFA date of August 25, 2026. Management expects Ziihera to become the HER2-targeted therapy of choice due to the magnitude of benefits observed in the HERIZON-GEA trial, including an unprecedented🌐 median overall survival of 26.4 months with the triplet arm.
Modeyso Launch Momentum and First-Line Potential
Modeyso generated strong early net product sales of $41 million in Q1 2026, following its launch in August 2025. Approximately 500 patients have been treated with Modeyso since launch, reflecting the significant unmet need in H3 K27M-mutant diffuse midline glioma. The company sees potential upsides in treatment duration and patient population size, especially with the ongoing Phase III ACTION trial, which is designed to support regulatory approval for frontline therapy directly following radiation, potentially expanding the market and duration of treatment.
Zepzelca Growth Driven by Frontline Maintenance
Zepzelca net product sales increased 60% year-over-year to $101 million in Q1 2026. This growth was primarily fueled by strong uptake in the frontline maintenance setting, following FDA approval in combination with Tecentriq in October of the prior year. Healthcare providers are rapidly adopting the Zepzelca combination due to the IMforte clinical data showing improved progression-free and overall survival for patients with extensive stage small cell lung cancer. While first-line maintenance adoption is expected to grow, second-line use is anticipated to decrease due to competition.
Pipeline Advancement Across Oncology and Neuroscience
Jazz Pharmaceuticals continues to make progress across its pipeline with multiple clinical trials. Key oncology trials include ongoing registrational zanidatamab trials, such as the EmpowHER trial in metastatic breast cancer (enrollment completion H1 2027, data late 2027/early 2028) and a potentially registrational pan-tumor basket trial. In neuroscience and epilepsy, early-stage assets are in development, with the company actively exploring new mechanisms and building around its Epidiolex franchise.
Financial Strength and Strategic Capital Allocation
The company reported a strong financial position with $2.9 billion in cash and investments and $408 million in cash from operations in Q1. This financial strength enables investment in commercial portfolio growth and pipeline advancement, alongside disciplined capital allocation for business development opportunities. Jazz is focused on expanding its presence in rare diseases, particularly strengthening existing areas like epilepsy, sleep, and rare oncology, and exploring new rare disease areas where it can leverage its capabilities.